

**Lab No.** : SG2/27-07-2024/SR9434159

Patient Name : AJAY PRATAP SINGH

**Age** : 34 Y 3 M 22 D

Gender : M

HbA1c (IFCC)

(Method:HPLC)

Lab Add. : Sevoke Road, Siliguri 734001

Ref Dr. : Dr.MEDICAL OFFICER

Collection Date : 27/Jul/2024 09:07AM

Report Date : 27/Jul/2024 12:51PM



#### DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Bio Ref. Interval	Unit
CALCIUM,BLOOD (Method:OCPC)	9.18	8.6-10.0 mg/dl	mg/L
GLUCOSE,PP (Method:Hexokinase Method)	116	75-140	mg/dl
BILIRUBIN (DIRECT) (Method:DIAZOTIZATION)	0.16	< 0.2	mg/dL
SGOT/AST (Method:UV WITH P5P)	<u>71</u>	15 - 37	U/L
SGPT/ALT (Method:UV WITH P5P)	118	16 - 63	U/L
SODIUM,BLOOD (Method:ISE INDIRECT)	136	136 - 145	mEq/L
CHLORIDE,BLOOD (Method:ISE INDIRECT)	108	98 - 107	mEq/L
CREATININE, BLOOD (Method: ALKALINE PICRATE)	0.87	0.70 - 1.30	mg/dl
GLUCOSE,FASTING (Method:Hexokinase Method)	94	70 - 100	mg/dl
PHOSPHORUS-INORGANIC,BLOOD (Method:UV PHOSPHOMOLYBDATE)	3.4	2.5-4.5 mg/dl	mg/dl
*TOTAL PROTEIN [BLOOD] ALB:GLO R	ATIO , .		
TOTAL PROTEIN (Method:BIURET METHOD)	7.65	6.6 - 8.7	g/dL
ALBUMIN (Mathod: BCB)	4	3.4-5.0 g/dl	g/dl
(Method:BCP) GLOBULIN (Method:Calculated)	3.68	1.8-3.2	g/dl
AG Ratio (Method:Calculated)	1.08	1.0 - 2.5	
*GLYCATED HAEMOGLOBIN (HBA1C),	EDTA WHOLE BLOOD		
GLYCATED HEMOGLOBIN (HBA1C)	5.4	***FOR BIOLOGICAL REFERENCE INTERVAL DETAILS , PLEASE REFER TO THE BELOW MENTIONED REMARKS/NOTE	%

## Clinical Information and Laboratory clinical interpretation on Biological Reference Interval:

35

Low risk / Normal / non-diabetic : <5.7% (NGSP) / < 39 mmol/mol (IFCC) Pre-diabetes/High risk of Diabetes : 5.7%- 6.4% (NGSP) / 39 - < 48 mmol/mol (IFCC) Diabetics-HbA1c level : >/= 6.5% (NGSP) / > 48 mmol/mol (IFCC)

mmol/mol

WITH ADDITIONAL CLINICAL

**INFORMATION** \*\*\*



 Patient Name
 : AJAY PRATAP SINGH
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 34 Y 3 M 22 D
 Collection Date
 : 27/Jul/2024 09:07AM

 Gender
 : M
 Report Date
 : 27/Jul/2024 12:51PM



#### DEPARTMENT OF BIOCHEMISTRY

Test Name Result Bio Ref. Interval Unit

Analyzer used : Bio-Rad D 10 Method : HPLC Cation Exchange

#### Recommendations for glycemic targets

- Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.
- Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.
- Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.
- Ø If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.
- Ø For most adults who are not pregnant, HbA1c levels should be <7% to help reduce microvascular complications and macrovascular disease . Action suggested >8% as it indicates poor control.
- Ø Some patients may benefit from HbA1c goals that are stringent.

Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after surgery, blood transfusions, hemolytic anemia, or high erythrocyte turnover; vitamin B12/ folate deficiency, presence of chronic renal or liver disease; after administration of high-dose vitamin E / C; or erythropoietin treatment.

Reference: Glycated hemoglobin monitoring BMJ 2006; 333;586-8

#### References:

- 1. Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published online 1 March 2016. doi:10.7326/M15-3016.
- 2. Mosca A, Goodall I, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007;45(8):1077-1080.

#### PDF Attached

PDF Attached			
LIPID PROFILE, GEL SERUM			
CHOLESTEROL-TOTAL (Method:CHOLESTEROL OXIDASE, ESTERASE,PEROXIDASE)	104	Desirable: < 200 mg/dL Borderline high: 200-239 High: > or =240 mg/d	mg/dl L
TRIGLYCERIDES (Method:ENZYMATIC, END POINT)	76	NORMAL < 150 BORDERLINE HIG 150-199 HIGH 200-499 VERY HIGH 500	9
HDL CHOLESTEROL (Method:DIRECT MEASURE-PEG)	<u>37</u>	NO RISK : >60 mg/dL, MODERATE RISK : 40-60 mg/dL, HIGH RISK : <br mg/dL	9
LDL CHOLESTEROL DIRECT (Method:DIRECT MEASURE)	63	OPTIMAL: <100 mg/dL, Near optimal/ above optimal: 100-129 mg/dL, Borderline high: 130-159 mg/dL, High: 160-189 mg/dL, Very high: >=190 mg/dL	mg/dl
VLDL (Method:Calculated)	4	< 40 mg/dl	mg/dL
CHOL HDL Ratio (Method:Calculated)	2.8	LOW RISK 3.3-4.4 AVERAGE RISK 4.47-7.1 MODERATE RISK 7.1-11. HIGH RISK >11.0	
*BILIRUBIN (TOTAL), GEL SERUM			
BILIRUBIN (TOTAL) (Method:DIAZONIUM ION )	0.56	0.2 - 1.2	mg/dL
ALKALINE PHOSPHATASE (Method:P-NPP,AMP BUFFER)	98	46 - 116	U/L
UREA,BLOOD (Method:UREASE-COLORIMETRIC)	17	12.8-42.8	mg/dl

**Lab No.** : SG2/27-07-2024/SR9434159 Page 2 of 10



 Patient Name
 : AJAY PRATAP SINGH
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 34 Y 3 M 22 D
 Collection Date
 : 27/Jul/2024 09:07AM

 Gender
 : M
 Report Date
 : 27/Jul/2024 12:51PM



#### DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Bio Ref. Interval	Unit
URIC ACID,BLOOD (Method:URICASE ,COLORICMETRIC )	6.87	3.5 - 7.2	mg/dl
POTASSIUM,BLOOD (Method:ISE INDIRECT)	4.34	3.5 - 5.1	mEq/L
*THYROID PANEL (T3, T4, TSH), GEL SERUM	1		
T3-TOTAL (TRI IODOTHYRONINE) (Method:CLIA)	1.4	0.60 - 1.81 ng/ml	ng/ml
T4-TOTAL (THYROXINE) (Method:CLIA)	10.8	4.5 - 10.9	microgram/dl
TSH (THYROID STIMULATING HORMONE) (Method:CLIA)	4.47	0.35-5.5	μIU/mL

#### BIOLOGICAL REFERENCE INTERVAL: [ONLY FOR PREGNANT MOTHERS]

Trimester specific TSH LEVELS during pregnancy:
FIRST TRIMESTER : 0.10 2.50 µ IU/mL
SECOND TRIMESTER : 0.20 3.00 µ IU/mL
THIRD TRIMESTER : 0.30 3.00 µ IU/mL

#### References:

1.Indian Thyroid Society guidelines for management of thyroid dysfunction during pregnancy. Clinical Practice Guidelines, New Delhi: Elsevier; 2012.

2. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum. Thyroid 2011;21:1081-25.

3. Dave A, Maru L, Tripathi M. Importance of Universal screening for thyroid disorders in first trimester of pregnancy. Indian J Endocr Metab [serial online] 2014 [cited 2014 Sep 25]; 18: 735-8. Available from: http://www.ijem.in/text.asp?2014/18/5/735/139221.

\*\*\* End Of Report \*\*\*

Dr. Ankush Chakraborty MBBS, MD (Path), IFCAP Consultant Pathologist Reg. No. 65992 (WBMC)

**Lab No.** : SG2/27-07-2024/SR9434159 Page 3 of 10



: 34 Y 3 M 22 D





**Collection Date** 



: Dr.MEDICAL OFFICER

: 27/Jul/2024 02:38PM

Lab No. : SG2/27-07-2024/SR9434159 Lab Add. : Newtown, Kolkata-700156

**Patient Name** : AJAY PRATAP SINGH Ref Dr.

Age

Report Date : 29/Jul/2024 12:20PM Gender : M



## DEPARTMENT OF BIOCHEMISTRY

Test Name Result Bio Ref. Interval Unit	
---	--

URIC ACID, URINE, SPOT URINE

URIC ACID, SPOT URINE 38 37-92 mg/dL mg/dL

(Method:URICASE)

\*\*\* End Of Report \*\*\*

MBBS, MD (Biochemistry) Consultant Biochemist Reg No. WBMC 73007

Lab No. SG2/27-07-2024/SR9434159





Page 5 of 10

Lab No. : SG2/27-07-2024/SR9434159

**Patient Name** : AJAY PRATAP SINGH

: 34 Y 3 M 22 D Age

Gender : M DIAGNOS

: Sevoke Road, Siliguri 734001

: 27/Jul/2024 09:07AM

: Dr.MEDICAL OFFICER Ref Dr.

: 27/Jul/2024 04:07PM Report Date



Lab Add.

**Collection Date** 

**Test Name** Result Bio Ref. Interval Unit

ESR (ERYTHROCYTE SEDIMENTATION RATE), EDTA WHOLE BLOOD

0.00 - 20.00 mm/hr 1stHour <u>30</u> mm/hr

(Method:Westergren)

BLOOD GROUP ABO+RH [GEL METHOD], EDTA WHOLE BLOOD

**ABO** 

(Method:Gel Card)

RH **POSITIVE** 

(Method:Gel Card)

Gel technology Dia Med ID Micro typing system is the latest technology in transfusion Medicine.

It gives more reproducible and standardized test results.

It more repaid, reliable, very sensitive and objective, and hence more consistent and comparable results are obtained.

Single used cards are individualised for every patient and results can be photographed / scanned and stored for future use.

Special instruments that are used only for this technology also reduce risk of any contamination.

Ref:- WHO technical manual on transfusion medicine-Second Edition 2003

(RESULTS ALSO VERIFIED BY: FORWARD AND REVERSE GROUPING (TUBE AND SLIDE METHOD)

#### **TECHNOLOGY USED: GEL METHOD**

#### ADVANTAGES:

- Gel card allows simultaneous forward and reverse grouping.
- Card is scanned and record is preserved for future reference.
- Allows identification of Bombay blood group.

DO WITH DI ATELET (THEOLOGO)/TE\ OOHNIT

Daily quality controls are run allowing accurate monitoring.

Historical records check not performed.

CBC WITH PLATELET (THROMBOCYTE) COUNT, EDTA WHOLE BLOOD					
HEMOGLOBIN (Method:SLS haemoglobin method)	13.5	13 - 17	g/dL		
WBC	4.3	4 - 10	*10^3/µL		
(Method:DC detection method) RBC	<u>4.35</u>	4.5 - 5.5	*10^6/µL		
(Method:DC detection method) PLATELET (THROMBOCYTE) COUNT (Method:DC detection method/Microscopy)	228	150 - 450*10^3	*10^3/µL		
DIFFERENTIAL COUNT					
NEUTROPHILS (Method:Flowcytometry/Microscopy)	47	40 - 80 %	%		
LYMPHOCYTES (Method:Flowcytometry/Microscopy)	<u>46</u>	20 - 40 %	%		
MONOCYTES	03	2 - 10 %	%		
(Method:Flowcytometry/Microscopy) EOSINOPHILS	04	1 - 6 %	%		
(Method:Flowcytometry/Microscopy) BASOPHILS (Method:Flowcytometry/Microscopy)	00	0-0.9%	%		
CBC SUBGROUP					
HEMATOCRIT / PCV (Method:Calculated)	<u>39</u>	40 - 50 %	%		
MCV	89.6	83 - 101 fl	fl		

Lab No. SG2/27-07-2024/SR9434159





MC-2176

**Lab No.** : SG2/27-07-2024/SR9434159

Patient Name : AJAY PRATAP SINGH

**Age** : 34 Y 3 M 22 D

Gender : M

Lab Add. : Sevoke Road, Siliguri 734001

**Ref Dr.** : Dr.MEDICAL OFFICER

Collection Date : 27/Jul/2024 09:07AM

Report Date : 27/Jul/2024 04:07PM



#### DEPARTMENT OF HAEMATOLOGY

Test Name	Result	Bio Ref. Interval	Unit	
(Method:Calculated)				
MCH (Method:Calculated)	31	27 - 32 pg	pg	
MCHC (Method:Calculated)	<u>34.7</u>	31.5-34.5 gm/dl	gm/dl	
RDW - RED CELL DISTRIBUTION WIDTH (Method:Calculated)	<u>14.9</u>	11.6-14%	%	
PDW-PLATELET DISTRIBUTION WIDTH (Method:Calculated)	21.9	8.3 - 25 fL	fL	
MPV-MEAN PLATELET VOLUME (Method:Calculated)	12.5	7.5 - 11.5 fl		
RBC	NORMOCYTIC NORMOCHROMIC.			
WBC.	NORMAL MORPHOLOGY			
PLATELET	ADEQUATE ON SMEAR.			

\*\*\* End Of Report \*\*\*

MBBS, MD (Path), IFCAP Consultant Pathologist Reg. No. 65992 (WBMC)

Dr. Ankush Chakraborty

**Lab No.** : SG2/27-07-2024/SR9434159



**Lab No.** : SG2/27-07-2024/SR9434159

Patient Name : AJAY PRATAP SINGH Ref Dr. : Dr.MEDICAL OFFICER

Age : 34 Y 3 M 22 D Collection Date

**Gender** : M Report Date : 27/Jul/2024 03:08PM

#### DEPARTMENT OF X-RAY

Lab Add.

#### X-RAY REPORT OF CHEST (PA)

#### **FINDINGS:**

Visualised lung fields show no significant abnormality except prominent perihilar vasculatures.

Domes of the diaphragm appear expiratory in position with normalcosto-phrenic angles.

Cardiac size appears marginally enlarged - likely due to expiratory position of the diaphragm.

Visualised thoracic bones show no significant abnormality.

Please correlate clinically.

\*\*\* End Of Report \*\*\*

DR. SUBHADRO GHOSE MD, CONSULTANT RADIOLOGIST

**Lab No.** : SG2/27-07-2024/SR9434159 Page 7 of 10





MC-2176

 Patient Name
 : AJAY PRATAP SINGH
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 34 Y 3 M 22 D
 Collection Date
 : 27/Jul/2024 09:18AM

 Gender
 : M
 Report Date
 : 27/Jul/2024 07:45PM



#### DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Result Bio Ref. Interval Unit

URINE ROUTINE ALL, ALL , URINE			
PHYSICAL EXAMINATION			
COLOUR	PALE YELLOW		
APPEARANCE	Clear		
CHEMICAL EXAMINATION			
рН	5.0	4.6 - 8.0	
(Method:Dipstick (triple indicator method))			
SPECIFIC GRAVITY	1.015	1.005 - 1.030	
(Method:Dipstick (ion concentration method)) PROTEIN	NEGATIVE	NOT DETECTED	
(Method:Dipstick (protein error of pH	NEGATIVE	NOT DETECTED	
ndicators)/Manual)			
GLUCOSE	NEGATIVE	NOT DETECTED	
(Method:Dipstick(glucose-oxidase-peroxidase			
nethod)/Manual) KETONES (ACETOACETIC ACID,	ABSENT	NOT DETECTED	
ACETONE)	ADSENT	NOT DETECTED	
(Method:Dipstick (Legals test)/Manual)			
BLOOD	NEGATIVE	NOT DETECTED	
(Method:Dipstick (pseudoperoxidase reaction))			
BILIRUBIN	NEGATIVE	NEGATIVE	
(Method:Dipstick (azo-diazo reaction)/Manual)	NICO ATIVE	NIFO A TIVE	
UROBILINOGEN (Method:Dipstick (diazonium ion reaction)/Manual)	NEGATIVE	NEGATIVE	
NITRITE	NEGATIVE	NEGATIVE	
(Method:Dipstick (Griess test))	1120/11112	1120/11112	
LEUCOCYTE ESTERASE	NEGATIVE	NEGATIVE	
(Method:Dipstick (ester hydrolysis reaction))			
MICROSCOPIC EXAMINATION			
LEUKOCYTES (PUS CELLS)	0 - 1	0-5	/hpf
(Method:Microscopy)			
EPITHELIAL CELLS (Method:Microscopy)	0 - 1	0-5	/hpf
RED BLOOD CELLS	ABSENT	0-2	/hpf
(Method:Microscopy)	ADOLIVI	0-2	лірі
CAST	ABSENT	NOT DETECTED	
(Method:Microscopy)			
CRYSTALS	ABSENT	NOT DETECTED	
(Method:Microscopy)		NOT DETECTED	
BACTERIA (Method:Microscopy)	FEW	NOT DETECTED	
YEAST	ABSENT	NOT DETECTED	
(Method:Microscopy)			
OTHERS	ABSENT		

#### Note:

- 1. All urine samples are checked for adequacy and suitability before examination.
- 2. Analysis by urine analyzer of dipstick is based on reflectance photometry principle. Abnormal results of chemical examinations are confirmed by manual methods.
- 3. The first voided morning clean-catch midstream urine sample is the specimen of choice for chemical and microscopic analysis.
- 4. Negative nitrite test does not exclude urinary tract infections.
- 5. Trace proteinuria can be seen in many physiological conditions like exercise, pregnancy, prolonged recumbency etc.
- 6. False positive results for glucose, protein, nitrite, urobilinogen, bilirubin can occur due to use of certain drugs, therapeutic dyes, ascorbic acid, cleaning agents used in urine collection container.
- 7. Discrepancy between results of leukocyte esterase and blood obtained by chemical methods with corresponding pus cell and red blood cell count by microscopy can

**Lab No.** : SG2/27-07-2024/SR9434159 Page 8 of 10





MC-2176

**Lab No.** : SG2/27-07-2024/SR9434159

Patient Name : AJAY PRATAP SINGH

**Age** : 34 Y 3 M 22 D

Gender : M

Lab Add. : Sevoke Road, Siliguri 734001

Ref Dr. : Dr.MEDICAL OFFICER

Collection Date : 27/Jul/2024 09:18AM

Report Date : 27/Jul/2024 07:45PM



## DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Result Bio Ref. Interval Unit

occur due to cell lysis.

8. Contamination from perineum and vaginal discharge should be avoided during collection, which may falsely elevate epithelial cell count and show presence of bacteria and/or yeast in the urine.

\*\*\* End Of Report \*\*\*

Dr. Ankush Chakraborty MBBS, MD (Path), IFCAP Consultant Pathologist Reg. No. 65992 (WBMC)

**Lab No.** : SG2/27-07-2024/SR9434159 Page 9 of 10

E-mail: info@surakshanet.com | Website: www.surakshanet.com



**Lab No.** : SG2/27-07-2024/SR9434159

Patient Name : AJAY PRATAP SINGH Ref Dr. : Dr.MEDICAL OFFICER

Age : 34 Y 3 M 22 D Collection Date

**Gender** : M Report Date : 27/Jul/2024 01:20PM



#### DEPARTMENT OF CARDIOLOGY

## DEPARTMENT OF CARDIOLOGY REPORT OF E.C.G.

Lab Add.

HEART RATE : 59 /min.

RHYTHM : Regular sinus.

P-WAVE : Normal

P - R INTERVAL : 160 ms, QRS DURATION : 80 ms

QRS CONFIGURATION : NORMAL

QRS VOLTAGE : R/S in V1 2/5 mm.

R/S in V6 5/3 mm.

QRS AXIS : -5°

Q- Waves : No significant Q-wave.

QT TIME : Normal.

ST SEGMENT : Normal.

T WAVE : NORMAL

ROTATION : Normal.

OTHER FINDINGS : Nil.

IMPRESSION : ECG WITHIN NORMAL LIMIT.


Dr. ARABINDA SAHA (MD,DM) CONSULTANT CARDIOLOGIST

**Lab No.** : SG2/27-07-2024/SR9434159 Page 10 of 10

# **Patient report**

Sample ID: D02135706802
Injection date 27/07/2024 02:30 AM
Injection #: 3 D-10 Method: HbA1c
Rack #: --- Rack position: 3

Bio-Rad v: 5.00-2 S/N: #DM23F10804



Peak table - ID: D02135706802

Peak	R.time	Height	Area	Area %
A1a	0.23	5861	36096	1.1
A1b	0.29	9267	37375	1.1
F	0.53	3949	19265	0.6
LA1c/CHb-1	0.66	6820	52468	1.6
A1c	0.86	15630	129156	5.4
P3	1.36	38588	183686	5.4
A0	1.43	1142425	2913942	86.4

Total Area: 3371990

Concentration:	%	mmol/mol
A1c	5.4	35